SPDL1 inhibition enhances colorectal cancer progression via epidermal growth factor receptor/extracellular signal-regulated kinase pathways

Table 1 Sequences of primers used for real-time polymerase chain reaction

Gene	Sequence (5’ to 3’)
SPDL1	Forward	GCTGCTGAATCAAAGCTTCAAACA
	Reverse	TTGAGGCAAGTGGCACCGTA
ACTB	Forward	GTCATTCCAAATATGAGATGCGT
	Reverse	GCTATCACCTCCCCTGTGTG

Table 2 Relationship between the expression of SPDL1 and clinicopathological features of colorectal cancer, n (%)

Clinicopathological characteristic	SPDL1		P value
	+	-
Sex			0.169
Male	48 (57.1)	36 (42.9)
Female	20 (44.4)	25 (55.6)
Age (years)			0.517
≤ 60	28 (50.9)	27 (49.1)
> 60	40 (54.1)	34 (45.9)
Tumor size			0.708
< 5 cm	47 (51.6)	44 (48.4)
≥ 5 cm	21 (55.3)	17 (44.7)
Tumor differentiation			0.034
Well	8 (80.0)	2 (20.0)
Moderate	58 (52.7)	52 (47.3)
Poor	2 (22.2)	7 (77.8)
Tumor-node-metastasis stage			0.033
I	15 (62.5)	9 (37.5)
II	30 (65.2)	16 (34.8)
III	19 (41.3)	27 (59.7)
IV	4 (30.8)	9 (69.2)
Depth of infiltration			0.975
T1 + T2	18 (52.9)	16 (47.1)
T3 + T4	50 (52.6)	45 (47.4)
Lymph node metastasis			0.02
N0	47 (62.7)	28 (37.3)
N1	12 (44.4)	15 (55.6)
N2	9 (33.3)	18 (66.7)
Distant metastasis			0.095
M0	64 (55.2)	52 (44.8)
M1	4 (30.8)	9 (69.2)